Iopromide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IV Contrast-enhanced computerized tomography As 300 mg iodine/mL: Head: 50-200 mL via IV inj. Max dose for procedure: 200 mL. Body: As single phase inj, 50-200 mL via IV bolus inj; 100-200 mL via rapid infusion. Max dose for procedure: 200 mL. As multiple phase inj, 50-200 mL via IV inj. Max dose for procedure: 200 mL. As 370 mg iodine/mL: Head: 41-162 mL via IV inj. Max dose for procedure: 162 mL. Body: As single phase inj, 41-162 mL via IV bolus inj; 81-162 mL via rapid infusion. Max dose for procedure: 162 mL. As multiple phase inj, 41-162 mL via IV inj. Max dose for procedure: 162 mL. Excretory urography As 300 mg iodine/mL: 1 mL/kg via IV infusion. Max dose for procedure: 100 mL. Intra-arterial Aortography and visceral angiography As 370 mg iodine/mL: Volume and rate of administration are based on the blood flow and specific characteristics of vessels being studied. Max dose for procedure: 225 mL. Cerebral arteriography As 300 mg iodine/mL: Carotid artery visualisation: 3-12 mL. Vertebral artery visualisation: 4-12 mL. Aortic arch inj: 20-50 mL. Max dose for procedure: 150 mL. Coronary arteriography and left ventriculography As 370 mg iodine/mL: Left or right coronary artery: 3-14 mL. Left ventricle: 30-60 mL. Max dose for procedure: 225 mL. Peripheral arteriography As 300 mg iodine/mL. Subclavian or femoral artery: 5-40 mL. Aortic bifurcation for distal runoff: 25-50 mL. Max dose for procedure: 250 mL.
Dosage Details
Intra-arterial
Cerebral arteriography
Adult: As 300 mg iodine/mL: Carotid artery visualisation: 3-12 mL. Vertebral artery visualisation: 4-12 mL. Aortic arch inj: 20-50 mL. Max dose for procedure: 150 mL.

Intra-arterial
Aortography and visceral angiography
Adult: As 370 mg iodine/mL: Volume and rate of administration are based on the blood flow and specific characteristics of vessels being studied. Max dose for procedure: 225 mL.

Intra-arterial
Peripheral arteriography
Adult: As 300 mg iodine/mL: Subclavian or femoral artery: 5-40 mL. Aortic bifurcation for distal runoff: 25-50 mL. Max dose for procedure: 250 mL.

Intra-arterial
Coronary arteriography and left ventriculography
Adult: As 370 mg iodine/mL: Left or right coronary artery: 3-14 mL. Left ventricle: 30-60 mL. Max dose for procedure: 225 mL.

Intravenous
Contrast-enhanced computerized tomography
Adult: As 300 mg of iodine/mL: Head: 50-200 mL via IV inj. Max dose for procedure: 200 mL. Body: As single phase inj, 50-200 mL via IV bolus inj; 100-200 mL via rapid infusion. Max dose for procedure: 200 mL. As multiple phase inj, 50-200 mL via IV inj. Max dose for procedure: 200 mL. As 370 mg of iodine/mL: Head: 41-162 mL via IV inj. Max dose for procedure: 162 mL. Body: As single phase inj, 41-162 mL via IV bolus inj; 81-162 mL via rapid infusion. Max dose for procedure: 162 mL. As multiple phase inj, 41-162 mL via IV inj. Max dose for procedure: 162 mL.
Child: >2 years As 300 mg iodine/mL: 1-2 mL/kg. Max dose for procedure: 3mL/kg.

Intravenous
Excretory urography
Adult: As 300 mg iodine/mL: 1 mL/kg via IV infusion. Max dose for procedure: 100 mL.
Child: >2 years As 300 mg iodine/mL: 1-2 mL/kg. Max dose for procedure: 3mL/kg.
Contraindications
Intrathecal administration.
Special Precautions
Patient with a history of hypersensitivity to contrast dye or iodine, and with known allergic disorders (e.g. bronchial asthma, hay fever, food allergies); advanced vascular disease, CV disease or heart failure, diabetes mellitus, thyroid disease, multiple myeloma, sickle cell disease, phaeochromocytoma, and dehydration. Renal and hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Extravasation, acute kidney injury, renal failure, severe cutaneous adverse reactions (e.g. Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalised exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms).
Cardiac disorders: Chest pain.
Eye disorders: Blurred vision.
Gastrointestinal disorders: Nausea, vomiting, abdominal pain.
General disorders and administration site conditions: Injection site pain.
Nervous system disorders: Headache, dizziness, dysgeusia.
Vascular disorders: Vasodilation, hypertension.
Potentially Fatal: Anaphylactic reactions. Rarely, thromboembolic events.
Intra-arterial/IV/Parenteral: B
MonitoringParameters
Monitor renal function, blood pressure, and hydration; signs of extravasation and hypersensitivity reactions during administration.
Overdosage
Symptoms: Fluid and electrolyte imbalance; CV and pulmonary complications; renal impairment. Management: Symptomatic and supportive treatment.
Drug Interactions
May increase the risk of lactic acidosis induced by biguanides (e.g. metformin). Increased prevalence of delayed hypersensitivity reactions with interleukins.
Lab Interference
May affect thromboplastin time, thrombin activity, and the accuracy of thyroid function tests assessment.
Action
Description: Iopromide is a nonionic iodinated radiographic contrast medium. It allows visualisation of internal body structures by opacifying the path of its flow.
Pharmacokinetics:
Distribution: Rapidly distributed in the extracellular fluid. Volume of distribution: 16 L. Plasma protein binding: 1%.
Excretion: Via urine (97% as unchanged drug); faeces (2%). Elimination half-life: 2 hours.
Chemical Structure

Chemical Structure Image
Iopromide_01

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 3736, Iopromide. https://pubchem.ncbi.nlm.nih.gov/compound/Iopromide. Accessed Oct. 26, 2020.

Storage
Store at 25°C. Protect from light.
ATC Classification
V08AB05 - iopromide ; Belongs to the class of watersoluble, nephrotropic, low osmolar preparations used as X-ray contrast media.
References
Anon. Iopromide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 17/08/2020.

Buckingham R (ed). Iopromide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 17/08/2020.

Iopromide. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com/. Accessed 17/08/2020.

Ultravist 300/370 Solution for Injection/Infusion (Bayer AG). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my/. Accessed 17/08/2020.

Ultravist 370 (Bayer plc). MHRA. https://products.mhra.gov.uk/. Accessed 17/08/2020.

Ultravist Injection (Bayer Healthcare Pharmaceuticals Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 17/08/2020.

Disclaimer: This information is independently developed by MIMS based on Iopromide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Ultravist
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in